OTCMKTS:FSNUY Fresenius SE & Co. Q1 2025 Earnings Results & Report $14.78 -0.01 (-0.07%) As of 03:59 PM Eastern Fresenius SE & Co. beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 7, 2025. The company reported EPS of $0.23 versus the $0.2170 consensus estimate, while revenue of $5.92 billion topped the $5.41 billion estimate by $513.12 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 7, 2025TimeBefore Market Opens Fresenius SE & Co. EPS ResultsActual EPS$0.23Consensus EPS $0.2170Beat/MissBeat by +$0.0130One Year Ago EPSN/AEPS Beat Rate4 of last 6 quartersFresenius SE & Co. Revenue ResultsActual Revenue$5.92 billionExpected Revenue$5.41 billionBeat/MissBeat by +$513.12 millionYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Fresenius SE & Co. Q1 2025 Earnings FAQ Did Fresenius SE & Co. beat earnings estimates for Q1 2025? Fresenius SE & Co. (OTCMKTS:FSNUY) reported earnings of $0.23 per share for Q1 2025, beating the consensus estimate of $0.2170. The report was announced on Wednesday, May 7, 2025. What was Fresenius SE & Co.'s revenue for Q1 2025? Fresenius SE & Co. reported revenue of $5.92 billion for Q1 2025, against a consensus estimate of $5.41 billion. Fresenius SE & Co. Earnings HeadlinesFresenius Kabi Launches Denosumab Biosimilars in Canada, with the First and Only Ready-to-Use Pre-Filled Syringe Biosimilar for OncologyNovember 16 at 9:28 AM | markets.ft.comFresenius plans to sell around 13.4 million FMC sharesNovember 11, 2026 | marketscreener.comMLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for $29.97, but it's available as a free download for a limited time.November 17 at 1:00 AM | Profits Run (Ad)Fresenius SE & Co. KGaA (FSNUY) Q3 2026 Earnings Call TranscriptNovember 4, 2026 | seekingalpha.comFresenius expands biosimilar business through partnership with China's WuXiNovember 3, 2026 | marketscreener.comMFresenius, WuXi Enter Development Agreement To Expand Biosimilars PipelineNovember 3, 2026 | rttnews.comSee More Fresenius SE & Co. Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email. Email Address About Fresenius SE & Co.Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA is a German healthcare group headquartered in Bad Homburg. Its businesses include Fresenius Kabi, which supplies medicines, clinical nutrition, infusion therapies and medical technologies, and Fresenius Helios, which operates hospitals in Germany and Spain. Fresenius Kabi serves healthcare providers around the world, while Helios focuses on hospital and healthcare services in Europe. The group traces its origins to a pharmacy in Frankfurt acquired by pharmacist Eduard Fresenius in 1912. Michael Sen has served as Fresenius’s chief executive officer since 2022. Through its businesses, the company provides products and services across areas including hospital care, pharmaceuticals and medical technology.View Fresenius SE & Co. ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.